2 Comments
User's avatar
Siobhan McHenry's avatar

Shouldn’t the question be, why is an athlete taking a Glp-1 ?

Carla DiGirolamo, MD's avatar

Yes! 100%. That is the central thesis of this 3 part series. When we see use of a medication surging in a population in which the use of the medication is understudied, it's important to start at square 1 and understand who these medications have and have not been studied in, what the data say about the indications, risks and benefits, and their physiologic effects. Once we have that understanding we are better positioned to answer that very question.